Loading…
← CockpitCompetitor Analysis › VITR.ST Vitrolife ABOpen in the cockpit ↗

Vitrolife ABVITR.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties

Swedish maker of laboratory equipment and culture media used in IVF and fertility clinics worldwide.

≈ A niche fertility-technology leader like a smaller CooperSurgicalMomentum leader 92
Mkt cap
$1.57B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$2.89M
20-day average traded
Fwd P/E
27.0×
forward earnings
ROIC−WACC
-5.7 pp
WACC 11.6%
Hurdle
-0 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · SEKSEK 117.70
1D0.0%
1W-0.5%
1M+20.4%
3M+29.3%
6M+12.7%
YTD-14.1%
1Y-17.6%
ATR %2.6%
52w lowhigh22.8% off high

What Vitrolife does

Swedish maker of laboratory equipment and culture media used in IVF and fertility clinics worldwide.

Culture media that clinics buy anew for every IVF cycle is a recurring line, so volumes follow treatment cycles, while incubators and imaging systems are capital purchases that lead to media sales. Genetic testing services were added by buying Igenomix.

In one line: A niche fertility-technology leader like a smaller CooperSurgical.

Products and services

  • Embryo culture media
  • IVF lab incubators/imaging systems
  • Micromanipulation tools

Customers

  • Fertility clinics
  • IVF laboratories

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • IVF/fertility lab equipment and…

What could go right

  • Rising global IVF cycle volumes
  • Emerging-market fertility clinic growth

What could go wrong

  • IVF reimbursement/funding policy risk
  • Competitive consumables pricing

Moat: narrow (installed base, customer qualification, brand). Leading global position in IVF consumables/equipment with embedded clinic workflows, though competition exists from larger medtech.

Headquarters: Gothenburg, Sweden · Founded: 1994 · Employees: 1,151

Named competitors

Vitrolife at a glance

Size Vitrolife (VITR.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $1.57B, the 100th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 117.70 on 18 Nov 2026.

Performance Over six months the shares gained 12.7%, against -2.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 1.9% over the last twelve months (peer median +8.6%); the operating margin is 19.2% (peer median 8.2%).

Valuation It trades at 27.0× forward earnings against a peer median of 22.0× (7th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.7 points below its cost of capital (11.6% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026VITR.ST 114Peer median 100
Six months, rebased to 100: Vitrolife against the median of its 20 peers (local-currency closes).

Vitrolife financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 3.44BSEK 3.44BSEK 3.61BSEK 3.51BSEK 3.23B
Revenue growth—-5%+3%+9%—
Gross profitSEK 1.80BSEK 1.75BSEK 1.88BSEK 1.74BSEK 1.55B
EBITDASEK 1.07BSEK 1.04BSEK 1.24BSEK 1.16BSEK 1.04B
Net income-SEK 4.96B-SEK 5.01BSEK 513M-SEK 3.85BSEK 394M
Free cash flowSEK 603MSEK 460MSEK 815MSEK 689MSEK 585M
Capital expenditureSEK 93.0MSEK 247MSEK 202MSEK 120MSEK 87.0M
Total debtSEK 1.73BSEK 1.60BSEK 2.09BSEK 2.09BSEK 2.23B

Quarterly statements and history in the cockpit →

Vitrolife competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%ENOV68853168496880163010876699BFLY8086ELNINSPKMTS300049300298PRCTEMBLACNMD301363LMATCHEMMVITR.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Vitrolife is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×ENOV688531684968801630108766998086ELNINSPXRAY300049EMBLACNMD301363LMATCHEMMVITR.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vitrolife is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ENOV68496880163010876699ELNINSP300049300298EMBLACNMD301363LMATCHEMMVITR.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Vitrolife is the large dot.

Vitrolife competitors and peer comparison

Head to head with its named competitors (VITR.ST vs COO vs MRK.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Vitrolife VITR.ST$1.57B+13%-2%19%27.0×22.2%
Cooper Companies (The) COO$11.6B-2%+5%19%13.4×9.4%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%

How Vitrolife compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vitrolife against its 20 peers (data as of 18 Nov 2026)
MeasureVITR.STPeer medianRank in peer set
1-month return+20.4%-1.1%4th highest of 21
6-month return+12.7%-2.3%6th highest of 21
Distance from 52-week high-22.8%-26.7%9th highest of 21
Revenue growth (TTM)-1.9%+8.6%lowest of 21
Operating margin19.2%8.2%6th highest of 21
Forward P/E27.0×22.0×7th most expensive of 18
Growth the price implies (Req g, 7 yrs)22.2%11.2%3rd most demanding of 16
Growth delivered (Del g)+22.5%+12.7%4th highest of 16
Hurdle (Req g minus delivered)-0.3 pp-6.8 pp8th most demanding of 16
ROIC minus cost of capital-5.7 pp+2.3 pp7th lowest of 21
EV / EBITDA15.7×11.8×5th most expensive of 11
Net debt / EBITDA0.8×-1.1×6th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%

Questions

Who are Vitrolife's main competitors?
Named competitors: CooperSurgical (CooperCompanies) (COO), Merck KGaA (fertility) (MRK.DE), Genea Biomedx (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Enovis (ENOV), Wuxi Unicomp Technology (688531.SS), Nihon Kohden (6849.T), Shanghai MicroPort Endovascular MedTech (688016.SS), Cofoe Medical Technology (301087.SZ), Angelalign Technology (6699.HK).
Is Vitrolife expensive compared with its peers?
On forward p/e it trades at 27.0× against a peer median of 22.0×, 7th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Vitrolife stock performed?
Over six months to 18 Nov 2026 the shares returned +12.7% against -2.3% for the median peer; over one year -17.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.